Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial - Takeaways - MDSpire

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

  • By

  • Solange Peters

  • Daniel S. W. Tan

  • David E. Gerber

  • James Urbanic

  • Suresh Ramalingam

  • Jinming Yu

  • Ligang Xing

  • Achim Rittmeyer

  • Tudor-Eliade Ciuleanu

  • Juliana de Menezes

  • Hye Ryun Kim

  • Carlos Rojas

  • Konstantinos Syrigos

  • Hidetoshi Hayashi

  • Anoop Haridass

  • Diego Cortinovis

  • Debora Bruno

  • Martin Kimmich

  • Antonio Calles

  • Raheel Nathani

  • Geetha Pudussery

  • Luoying Yang

  • Dirk De Ruysscher

  • May 13, 2026

  • 0 min

Share

  • 1

    The phase 3 CheckMate 73L study evaluated nivolumab with chemoradiotherapy followed by nivolumab alone or with ipilimumab in stage III NSCLC.

  • 2

    The study included 1,787 participants, with 925 randomized to three treatment arms: nivolumab plus ipilimumab, nivolumab alone, and durvalumab.

  • 3

    No significant difference in progression-free survival (PFS) was found between the nivolumab plus ipilimumab and durvalumab arms, with median PFS of 16.7 and 15.6 months, respectively.

  • 4

    Descriptive analysis indicated median overall survival (OS) was 34.6 months for nivolumab plus ipilimumab and 40.2 months for durvalumab, but OS was not formally tested.

  • 5

    The study highlights the need for improved treatment regimens for stage III NSCLC, as current therapies still result in significant disease progression.

Original Source(s)

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

  • by Solange Peters, Daniel S. W. Tan, David E. Gerber, James Urbanic, Suresh Ramalingam, Jinming Yu, Ligang Xing, Achim Rittmeyer, Tudor-Eliade Ciuleanu, Juliana de Menezes, Hye Ryun Kim, Carlos Rojas, Konstantinos Syrigos, Hidetoshi Hayashi, Anoop Haridass, Diego Cortinovis, Debora Bruno, Martin Kimmich, Antonio Calles, Raheel Nathani, Geetha Pudussery, Luoying Yang, Dirk De Ruysscher

  • May 13, 2026

Related Content

Machine learning–based prediction of mortality in lung cancer: Application of severity-adjustment method

Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report

Understanding cardiac toxicity and immune responses to thoracic radiation therapy in non-small cell lung cancer – implications for future research